Literature DB >> 31637449

The role of E3 ubiquitin ligase HECTD3 in cancer and beyond.

Qiuyun Jiang1,2, Fubing Li3, Zhuo Cheng1,2, Yanjie Kong4, Ceshi Chen5,6,7.   

Abstract

Ubiquitin modification plays significant roles in protein fate determination, signaling transduction, and cellular processes. Over the past 2 decades, the number of studies on ubiquitination has demonstrated explosive growth. E3 ubiquitin ligases are the key enzymes that determine the substrate specificity and are involved in cancer. Several recent studies shed light on the functions and mechanisms of HECTD3 E3 ubiquitin ligase. This review describes the progress in the recent studies of HECTD3 in cancer and other diseases. We propose that HECTD3 is a potential biomarker and a therapeutic target, and discuss the future directions for HECTD3 investigations.

Entities:  

Keywords:  Cancer; HECTD3; Inhibitors; Ubiquitination

Mesh：

Substances：

Year:  2019        PMID： 31637449     DOI： 10.1007/s00018-019-03339-3

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN： 1420-682X            Impact factor:   9.261


  111 in total

1.  Bortezomib.

Authors:  Andrew Paramore; Simon Frantz
Journal:  Nat Rev Drug Discov       Date:  2003-08       Impact factor: 84.694

Review 2.  The impact of in silico screening in the discovery of novel and safer drug candidates.

Authors:  Didier Rognan
Journal:  Pharmacol Ther       Date:  2017-02-14       Impact factor: 12.310

3.  Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells.

Authors:  Ceshi Chen; Xiaodong Sun; Peng Guo; Xue-Yuan Dong; Pooja Sethi; Xiaohong Cheng; Jun Zhou; Junxiu Ling; Jonathan W Simons; Jerry B Lingrel; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2005-10-13       Impact factor: 5.157

4.  High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1.

Authors:  Dana Ungermannova; Junglim Lee; Gan Zhang; H Garry Dallmann; Charles S McHenry; Xuedong Liu
Journal:  J Biomol Screen       Date:  2013-04-15

5.  c-Abl phosphorylates E6AP and regulates its E3 ubiquitin ligase activity.

Authors:  Ai-Leen Chan; Tamar Grossman; Valentina Zuckerman; Dafne Campigli Di Giammartino; Ofra Moshel; Martin Scheffner; Brendon Monahan; Pat Pilling; Yong-Hui Jiang; Sue Haupt; Ora Schueler-Furman; Ygal Haupt
Journal:  Biochemistry       Date:  2013-04-26       Impact factor: 3.162

6.  The paracaspase MALT1 controls caspase-8 activation during lymphocyte proliferation.

Authors:  Holli Kawadler; Mary A Gantz; James L Riley; Xiaolu Yang
Journal:  Mol Cell       Date:  2008-08-08       Impact factor: 17.970

7.  Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.

Authors:  Ariel G Herman; Miki Hayano; Masha V Poyurovsky; Kenichi Shimada; Rachid Skouta; Carol Prives; Brent R Stockwell
Journal:  Cancer Discov       Date:  2011-07-28       Impact factor: 39.397

8.  Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity.

Authors:  Zaidoun Salah; Gerry Melino; Rami I Aqeilan
Journal:  Cancer Res       Date:  2011-01-06       Impact factor: 12.701

9.  An integrated bioinformatics platform for investigating the human E3 ubiquitin ligase-substrate interaction network.

Authors:  Yang Li; Ping Xie; Liang Lu; Jian Wang; Lihong Diao; Zhongyang Liu; Feifei Guo; Yangzhige He; Yuan Liu; Qin Huang; Han Liang; Dong Li; Fuchu He
Journal:  Nat Commun       Date:  2017-08-24       Impact factor: 14.919

10.  Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression.

Authors:  Rong Liu; Peiguo Shi; Zhi Nie; Huichun Liang; Zhongmei Zhou; Wenlin Chen; Haijun Chen; Chao Dong; Runxiang Yang; Suling Liu; Ceshi Chen
Journal:  Theranostics       Date:  2016-02-13       Impact factor: 11.556
View more
  8 in total

1.  Lower expression of PDZRN3 induces endometrial carcinoma progression via the activation of canonical Wnt signaling.

Authors:  Qiuhong Li; Jie Zhong; Shangjie Yang; Yanping Liang
Journal:  Oncol Lett       Date:  2022-01-27       Impact factor: 2.967

2.  Impaired G2/M cell cycle arrest induces apoptosis in pyruvate carboxylase knockdown MDA-MB-231 cells.

Authors:  Khanti Rattanapornsompong; Janya Khattiya; Phatchariya Phannasil; Narumon Phaonakrop; Sittiruk Roytrakul; Sarawut Jitrapakdee; Chareeporn Akekawatchai
Journal:  Biochem Biophys Rep       Date:  2021-01-12

3.  Hypothermic oxygenated perfusion inhibits HECTD3-mediated TRAF3 polyubiquitination to alleviate DCD liver ischemia-reperfusion injury.

Authors:  Shaojun Ye; Qifa Ye; Wei Zhou; Zibiao Zhong; Danni Lin; Zhongzhong Liu; Qiuyan Zhang; Haoyang Xia; Sheng Peng; Anxiong Liu; Zhongshan Lu; Yanfeng Wang
Journal:  Cell Death Dis       Date:  2021-02-24       Impact factor: 8.469

4.  HIF-1α Induces HECTD2 Up-Regulation and Aggravates the Malignant Progression of Renal Cell Cancer via Repressing miR-320a.

Authors:  Dong Lv; Taimin Shen; Juncheng Yao; Qi Yang; Ying Xiang; Zhiwei Ma
Journal:  Front Cell Dev Biol       Date:  2021-12-24

Review 5.  E3 ubiquitin ligases: styles, structures and functions.

Authors:  Quan Yang; Jinyao Zhao; Dan Chen; Yang Wang
Journal:  Mol Biomed       Date:  2021-07-30

6.  HECTD3 promotes gastric cancer progression by mediating the polyubiquitination of c-MYC.

Authors:  Guanghui Zhang; Qingzong Zhu; Xiaomin Yan; Mingxin Ci; Erhu Zhao; Jianbing Hou; Sicheng Wan; Muhan Lü; Hongjuan Cui
Journal:  Cell Death Discov       Date:  2022-04-09

7.  Targeting HECTD3-IKKα axis inhibits inflammation-related metastasis.

Authors:  Fubing Li; Huichun Liang; Hua You; Ji Xiao; Houjun Xia; Xi Chen; Maobo Huang; Zhuo Cheng; Chuanyu Yang; Wenjing Liu; Hailin Zhang; Li Zeng; Yingying Wu; Fei Ge; Zhen Li; Wenhui Zhou; Yi Wen; Zhongmei Zhou; Rong Liu; Dewei Jiang; Ni Xie; Bin Liang; Zhenzhen Liu; Yanjie Kong; Ceshi Chen
Journal:  Signal Transduct Target Ther       Date:  2022-08-03

8.  FBXL16 Promotes Endometrial Progesterone Resistance via PP2AB55α /Cyclin D1 Axis in Ishikawa.

Authors:  Haoen Liu; Li Han; Liyan Zhong; Xiaodan Zhuang; Yan Peng
Journal:  J Immunol Res       Date:  2022-09-05       Impact factor: 4.493
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.